Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir

Journal of Hepatology

Volumn 53, Issue 3, 2010, Pages 449-454

  Heo, Nae Yun ^a   Lim, Young Suk ^a   Lee, Han Chu ^a   Chung, Young Hwa ^a   Lee, Yung Sang ^a   Suh, Dong Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Adefovir; Chronic hepatitis B; Entecavir; Lamivudine; Multidrug resistance

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; DRUG EFFICACY; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS MUTATION;

ADENINE; ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENES, VIRAL; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PHOSPHONIC ACIDS; VIRAL LOAD;

EID: 77955849324     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.03.020     Document Type: Article

References (48)

1. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of chronic hepatitis B J Hepatol 50 2009 227 242
2. E.B. Keeffe, D.T. Dieterich, S.H. Han, I.M. Jacobson, P. Martin, and E.R. Schiff A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update Clin Gastroenterol Hepatol 6 2008 1315 1341
3. A.S. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
4. Y.F. Liaw Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy Antivir Ther 11 2006 669 679
5. V. Di Marco, A. Marzano, P. Lampertico, P. Andreone, T. Santantonio, and P.L. Almasio Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine Hepatology 40 2004 883 891
6. G.V. Papatheodoridis, E. Dimou, K. Dimakopoulos, S. Manolakopoulos, I. Rapti, and G. Kitis Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine Hepatology 42 2005 121 129
7. B.C. Song, D.J. Suh, H.C. Lee, Y.H. Chung, and Y.S. Lee Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea Hepatology 32 2000 803 806
8. M.G. Ghany, and E.C. Doo Antiviral resistance and hepatitis B therapy Hepatology 49 2009 S174 S184
9. A.S. Lok, F. Zoulim, S. Locarnini, A. Bartholomeusz, M.G. Ghany, and J.M. Pawlotsky Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management Hepatology 46 2007 254 265
10. A.S. Lok, C.L. Lai, N. Leung, G.B. Yao, Z.Y. Cui, and E.R. Schiff Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 2003 1714 1722
11. T.T. Chang, C.L. Lai, R.N. Chien, R. Guan, S.G. Lim, and C.M. Lee Four years of lamivudine treatment in Chinese patients with chronic hepatitis B J Gastroenterol Hepatol 19 2004 1276 1282
12. M.G. Peters, H. Hann Hw, P. Martin, E.J. Heathcote, P. Buggisch, and R. Rubin Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B Gastroenterology 126 2004 91 101
13. E.B. Keeffe, D.T. Dieterich, S.H. Han, I.M. Jacobson, P. Martin, and E.R. Schiff A treatment algorithm for the management of chronic hepatitis B virus infection in the United States Clin Gastroenterol Hepatol 2 2004 87 106
14. A.S. Lok, and B.J. McMahon Chronic hepatitis B: update of recommendations Hepatology 39 2004 857 861
15. R. de Franchis, A. Hadengue, G. Lau, D. Lavanchy, A. Lok, and N. McIntyre EASL International Consensus Conference on Hepatitis B, 13-14 September 2002, Geneva, Switzerland. Consensus statement (long version) J Hepatol 39 2003 S3 S25
16. S.K. Fung, H.B. Chae, R.J. Fontana, H. Conjeevaram, J. Marrero, and K. Oberhelman Virologic response and resistance to adefovir in patients with chronic hepatitis B J Hepatol 44 2006 283 290
17. Y.S. Lee, D.J. Suh, Y.S. Lim, S.W. Jung, K.M. Kim, and H.C. Lee Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy Hepatology 43 2006 1385 1391
18. J.E. Yeon, W. Yoo, S.P. Hong, Y.J. Chang, S.K. Yu, and J.H. Kim Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil Gut 55 2006 1488 1495 (Pubitemid 44476796)
19. H.J. Yim, M. Hussain, Y. Liu, S.N. Wong, S.K. Fung, and A.S. Lok Evolution of multi-drug resistant hepatitis B virus during sequential therapy Hepatology 44 2006 703 712
20. J.H. Shim, D.J. Suh, K.M. Kim, Y.S. Lim, H.C. Lee, and Y.H. Chung Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone Hepatology 50 2009 1064 1071
21. E.B. Keeffe, S. Zeuzem, R.S. Koff, D.T. Dieterich, R. Esteban-Mur, and E.J. Gane Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B Clin Gastroenterol Hepatol 5 2007 890 897
22. M.F. Yuen, E. Sablon, C.K. Hui, H.J. Yuan, H. Decraemer, and C.L. Lai Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy Hepatology 34 2001 785 791
23. F. Zoulim, M. Buti, and A.S. Lok Antiviral-resistant hepatitis B virus: can we prevent this monster from growing? J Viral Hepat 14 2007 29 36
24. M.F. Yuen, J. Fung, D.K. Wong, and C.L. Lai Prevention and management of drug resistance for antihepatitis B treatment Lancet Infect Dis 9 2009 256 264
25. S.K. Fung, P. Andreone, S.H. Han, K. Rajender Reddy, A. Regev, and E.B. Keeffe Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation J Hepatol 43 2005 937 943
26. I. Rapti, E. Dimou, P. Mitsoula, and S.J. Hadziyannis Adding-on versus switching to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B Hepatology 45 2007 307 313
27. P. Lampertico, M. Vigano, E. Manenti, M. Iavarone, E. Sablon, and M. Colombo Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients Gastroenterology 133 2007 1445 1451
28. S. Gaia, V. Barbon, A. Smedile, A. Olivero, S. Carenzi, and M. Lagget Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine J Hepatol 48 2008 540 547
29. H. Yatsuji, F. Suzuki, H. Sezaki, N. Akuta, Y. Suzuki, and Y. Kawamura Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up J Hepatol 48 2008 923 931
30. A.S. Lok, and B.J. McMahon Chronic hepatitis B Hepatology 45 2007 507 539
31. M.N. Brunelle, A.C. Jacquard, C. Pichoud, D. Durantel, S. Carrouee-Durantel, and J.P. Villeneuve Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir Hepatology 41 2005 1391 1398
32. J.P. Villeneuve, D. Durantel, S. Durantel, C. Westland, S. Xiong, and C.L. Brosgart Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient J Hepatol 39 2003 1085 1089
33. S. Villet, C. Pichoud, G. Billioud, L. Barraud, S. Durantel, and C. Trepo Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure J Hepatol 48 2008 747 755
34. R. Gerolami, M. Bourliere, P. Colson, P. Halfon, P. Borentain, and M. Henry Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases Antivir Ther 11 2006 1103 1106
35. T.T. Chang, R.G. Gish, S.J. Hadziyannis, J. Cianciara, M. Rizzetto, and E.R. Schiff A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients Gastroenterology 129 2005 1198 1209
36. M. Sherman, C. Yurdaydin, J. Sollano, M. Silva, Y.F. Liaw, and J. Cianciara Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B Gastroenterology 130 2006 2039 2049 (Pubitemid 43816960)
37. S.J. Hadziyannis, and D. Vassilopoulos Hepatitis B e antigen-negative chronic hepatitis B Hepatology 34 2001 617 624
38. J.L. Dienstag Hepatitis B virus infection N Engl J Med 359 2008 1486 1500
39. S.J. Hadziyannis, N.C. Tassopoulos, E.J. Heathcote, T.T. Chang, G. Kitis, and M. Rizzetto Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years Gastroenterology 131 2006 1743 1751
40. C. Pallier, C. Rodriguez, R. Brillet, P. Nordmann, C. Hezode, and J.M. Pawlotsky Complex dynamics of hepatitis B virus resistance to adefovir Hepatology 49 2009 50 59
41. X. Qi, S. Xiong, H. Yang, M. Miller, and WEt. Delaney In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents Antivir Ther 12 2007 355 362
42. J.G. Reijnders, S.D. Pas, M. Schutten, R.A. de Man, and H.L. Janssen Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy J Hepatol 50 2009 674 683
43. J. Tan, B. Degertekin, S.N. Wong, M. Husain, K. Oberhelman, and A.S. Lok Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations J Hepatol 48 2008 391 398
44. J. Trojan, M. Stuermer, G. Teuber, A. Berger, and D. Faust Treatment of patients with lamivudine-resistant and adefovir dipivoxil-resistant chronic hepatitis B virus infection: is tenofovir the answer? Gut 56 2007 436 437 author reply 437
45. F. van Bommel, R.A. de Man, H. Wedemeyer, K. Deterding, J. Petersen, and P. Buggisch Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues Hepatology 51 2010 73 80
46. J. Schollmeyer, M. Lutgehetmann, T. Volz, A.W. Lohse, P. Buggisch, and T.H. Meyer Combination of entecavir and tenofovir as a rescue therapy is safe and highly efficient in cirrhotic HBV mono-infected patients with the history of multiple previous treatment failures Hepatology 48 2008 749A
47. J. Schollmeyer, M. Lutgehetmann, T. Volz, C. Sarrazin, A.W. Lohse, and P. Buggisch Switching to adefovir plus entecavir is effective and leads to strong viral suppression in HBV mono-infected patients failing sequential or combination therapy with lamivudine and adefovir Hepatology 48 2008 721A
48. W.H. Choe, S.Y. Kwon, B.K. Kim, S.Y. Ko, J.E. Yeon, and K.S. Byun Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis Liver Int 28 2008 814 820